Protalix BioTherapeutics (PLX) Tops Q1 EPS by 18c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.59 -0.77%
Revenue Growth %: -33.6%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES: -6.35M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Revenue Growth %: -33.6%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES: -6.35M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of $0.22, $0.18 better than the analyst estimate of $0.04. Revenue for the quarter came in at $33.75 million versus the consensus estimate of $18.7 million.
GUIDANCE:
Protalix BioTherapeutics sees FY2026 revenue of $78-83 million, versus the consensus of $79.1 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kosmos Energy (KOS) Misses Q3 EPS by 3c
- Morgan Stanley Upgrades Delhivery Ltd (DELHIVER:IN) to Overweight
- Jones Trading Starts Azora Therapeutics (AZR) at Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
